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receiving imatinib since less than 5 years. Patients were 
allocated 1:1 to “routine TDM” or “rescue TDM.” The 
primary endpoint was a combined outcome (failure- and 
toxicity-free survival with continuation on imatinib) 
over 1-year follow-up, analyzed in intention-to-treat 
(ISRCTN31181395).
Results Among 56 patients (55 evaluable), 14/27 (52 %) 
receiving “routine TDM” remained event-free versus 16/28 
(57 %) “rescue TDM” controls (P = 0.69). In the “rou-
tine TDM” arm, dosage recommendations were correctly 
adopted in 14 patients (median Cmin: 895 ng/ml), who had 
fewer unfavorable events (28 %) than the 13 not receiving 
the advised dosage (77 %; P = 0.03; median Cmin: 648 ng/
ml).
Conclusions This first target concentration intervention 
trial could not formally demonstrate a benefit of “routine 
TDM” because of small patient number and surprisingly 
limited prescriber’s adherence to dosage recommendations. 
Abstract 
Purpose This study assessed whether a cycle of “routine” 
therapeutic drug monitoring (TDM) for imatinib dosage 
individualization, targeting an imatinib trough plasma con-
centration (Cmin) of 1,000 ng/ml (tolerance: 750–1,500 ng/
ml), could improve clinical outcomes in chronic myelog-
enous leukemia (CML) patients, compared with TDM use 
only in case of problems (“rescue” TDM).
Methods Imatinib concentration monitoring evalua-
tion was a multicenter randomized controlled trial includ-
ing adult patients in chronic or accelerated phase CML 
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Favorable outcomes were, however, found in patients actu-
ally elected for target dosing. This study thus shows first 
prospective indication for TDM being a useful tool to guide 
drug dosage and shift decisions. The study design and anal-
ysis provide an interesting paradigm for future randomized 
TDM trials on targeted anticancer agents.
Keywords Individualized medicine · Protein kinase 
inhibitors · Drug monitoring · Pharmacokinetics · 
Medication adherence
Introduction
The tyrosine kinase inhibitor (TKI) imatinib (Gleevec®, 
Glivec®; Novartis Pharma, Basel, Switzerland) is a first-
line treatment of chronic myeloid leukemia (CML) and 
has impressively improved the survival of CML patient 
[1, 2]. Second generation TKIs become increasingly avail-
able, showing a reduction in disease progression rates, 
yet without clear survival advantage [3]. Imatinib is pre-
scribed at fixed dosage of 400 mg once daily in chronic 
phase CML and 600 mg in accelerated phase, but discus-
sions about the optimal dose are still ongoing [4–6]. In 
practice, more than 30 % of patients discontinue imatinib 
because of unsatisfactory efficacy or intolerance [7, 8], 
which might be partly overcome by appropriate dosage 
modifications [9].
The systematic use of high-dose imatinib as standard 
treatment has not demonstrated a risk-benefit improvement, 
as it increases toxic effects without clear therapeutic advan-
tage [10]. Individualized dosage approaches are not well 
defined [11]. The prescribing information [12] and treat-
ment recommendations [13, 14] mention dosage individu-
alization based on the follow-up of adverse events (AEs) 
and response markers. Those pharmacodynamic markers, 
namely hematologic, cytogenetic and molecular responses, 
are surrogate predictors of overall survival, event-free and 
progression-free survival [14].
Several authors have suggested as well to use circulat-
ing imatinib concentrations as a pharmacokinetic pre-
dictor of response, to be monitored for dosage individu-
alization (therapeutic drug monitoring, TDM) [15–17]. 
Inter-patient variability of imatinib pharmacokinetics 
is indeed important, with trough concentrations (Cmin) 
varying by 55–106 % between patients under a given dos-
age [18]. The standard dosage is thus expected to produce 
sub- or supratherapeutic drug exposure in a significant frac-
tion of patients [9, 14, 18]. Since imatinib Cmin correlates 
with pharmacodynamic response [18–20], TDM has been 
proposed for selected cases with clinical concerns (called 
“rescue TDM” thereafter), e.g., to evaluate drug–drug inter-
actions, acute adherence problems [14] or potential sources 
of suboptimal efficacy or tolerance [15, 17, 21]. Despite 
the limited evidence supporting the usefulness of this “res-
cue TDM” to correct such issues, efforts have been made 
during the past years to offer it to problematic patients. 
An ounce of prevention being worth a pound of cure, one 
might consider offering TDM-based dosage adjustment to 
all patients receiving imatinib. However, to date, a formal 
evaluation of “routine TDM” of imatinib is lacking [22] 
regarding its usefulness to prevent unfavorable outcomes. 
In addition, prospective randomized controlled trials vali-
dating the proposed therapeutic concentration ranges are 
still awaited [23, 24].
Therefore, we set up a prospective randomized trial aim-
ing to evaluate whether a “routine TDM” intervention with 
dosage adjustment, targeting imatinib Cmin of 1,000 ng/ml 
[17, 18] (tolerance interval: 750–1,500 ng/ml) could keep 
patients away from treatment failure, moderate to severe 
AEs or treatment discontinuation. Given that “rescue 
TDM” was already available in case of unsatisfactory ther-
apeutic response, ethical considerations made us decide not 
to deny TDM access to patients in the control group, but to 
merely limit “rescue TDM” to an on-need basis.
Methods
Study design and patients
Imatinib concentration monitoring evaluation (I-COME) 
was an investigator-initiated, multicenter, parallel, open-
label, randomized Swiss study [19]. It included CML 
patients aged ≥18 years, in chronic or accelerated phase, 
receiving imatinib since ≤5 years. Patients were recruited 
by hospital and ambulatory care hematologists. The pro-
tocol was approved by appropriate regional Swiss ethics 
committees [25].
Randomization and masking
Patients were randomly assigned (1:1) to either the inter-
vention (“routine TDM”) or the control group (“rescue 
TDM”) by the coordinating center (Division of Clinical 
Pharmacology, Lausanne). Scratch-off concealed allocation 
lists were used, based on variable size block randomization 
stratified in three layers, corresponding to the duration of 
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imatinib treatment (0–18/>18–36/>36–60 months). Neither 
the investigators nor the patients were blinded for treatment 
assignment.
Procedures
A plasma sample was drawn for study inclusion during a 
regular medical visit from all patients having given their 
informed consent. The sample was advised to be drawn 
≥4 h after drug intake and was sent to the coordinating 
center for imatinib concentration measurement, where 
patients were randomized, along with a laboratory request 
which simultaneously served as case report form for drug 
administration details, treatment response and tolerance. 
A validated Bayesian method was used to extrapolate the 
measured concentration to Cmin [26]. All patients were 
asked a last blood sample after 1 year.
Patients allocated to the control group received nei-
ther the result of their imatinib concentration nor a dos-
age recommendation at study inclusion, unless specifically 
requested because of clinical concerns (“rescue TDM”).
For patients allocated to the intervention group (“routine 
TDM”), a dosage recommendation was given to practition-
ers targeting a Cmin of 1,000 ng/ml [19, 20] (tolerance inter-
val 750–1,500 ng/ml). Additional TDM could be requested 
at any time, and a control measurement was recommended 
in case of dosage change or suspected non-compliance, 
after at least 1 week of regular drug intake to ensure steady-
state attainment. In the absence of established upper con-
centration limits, dosage decrease was only proposed 
if Cmin > 1,500 ng/ml went along with moderate (grade 
2) clinical or severe (grade 3) laboratory AEs (accord-
ing to Common Terminology Criteria for Adverse Events 
(CTCAE) version 4.0). The procedure of dosage recom-
mendations is summarized and illustrated in Fig. 1.
Imatinib plasma concentrations were measured by liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) 
[27, 28]. AEs were graded by the physician in charge and 
reported along with TDM requests. Assessments of cytoge-
netic and molecular response were performed as usual 
and collected by the investigators. Due to varying analyti-
cal sensitivities, BCR-ABL/ABL results were censored at 
<0.01 % IS (10−4). Complete cytogenetic response (CCR) 
was assumed under BCR-ABL/ABL values <1 % IS [29] 
when no measurement was available.
Statistical analysis
Analyses were performed according to intention-to-treat. 
The primary endpoint was the percentage of patients 
remaining event-free during the 1-year study follow-
up, i.e., remaining without treatment failure [4], disease 
progression, occurrence of moderate clinical or severe 
laboratory AEs, or treatment discontinuation. A sample size 
of 300 patients was targeted (90 % power at the 5 % signifi-
cance level for a decrease from 35 to 20 %, two-sided χ2 
test). The study had, however, to be closed after the sched-
uled recruitment period of 2 years with only 56 patients 
included. The primary outcome was also described as time-
to-event variable using Kaplan–Meier plots. Given that half 
of the patients in the intervention group did not or only par-
tially receive the recommended dosage (Fig. 2), a post hoc 
exploratory subgroup analysis of the primary outcome was 
performed in this group.
Secondary endpoints were as follows: percentage of 
patients achieving major molecular response (MMR) and 
CCR, remaining without moderate AEs, presenting clini-
cal concerns at inclusion and improving over 1 year, with 
imatinib Cmin above 1,000 ng/ml [19, 20]/within tolerance 
interval (Fisher’s exact test); median reduction of BCR-
ABL/ABL transcripts (Friedman test); predictive perfor-
mance of total and free Cmin for failure and AEs as defined 
in the primary endpoint (details are provided in the Online 
Resource 1); and compliance of practitioners toward dos-
age advice. Planned correlations of co-medication and 
genetic factors influencing imatinib pharmacokinetics with 
clinical outcomes could not be analyzed due to limited 
patient number.
The study was registered with Current Controlled Trials, 
number ISRCTN31181395.
Role of the funding source
A research grant and logistic support for the study was pro-
vided by Novartis (Bern, Switzerland). The study was also 
partly financed by the Swiss National Science Foundation 
(Nano-Tera initiative, ISyPeM project). The trial sponsor 
(Division of Clinical Pharmacology, Lausanne) had full 
responsibility for the study design, data collection, analy-
sis, interpretation and manuscript writing. The data are the 
property of the sponsor, but Novartis was granted access to 
anonymized study data. Novartis had no role in the design 
and analysis of the trial, result interpretation and final con-
tent. None of the authors were paid for manuscript writing. 
The authors had full access to all the study data and had the 
final responsibility and decision to submit the manuscript 
for publication.
Results
Study population
Between September 1, 2009 and August 30, 2011, 56 
patients were included and randomized (Table 1). Median 
duration of imatinib treatment at inclusion was 21 months, 
1310 Cancer Chemother Pharmacol (2014) 74:1307–1319
1 3
and median duration of study follow-up 13 months. In the 
“routine TDM” group, 15/28 of patients received the rec-
ommended dosage, 6/28 did not and 7/28 only partially 
(Fig. 2). In the control group, 12/28 patients requested 
“rescue TDM” during the study, including 8 already at 
inclusion (Fig. 2). In total, 13 patients (23 %) discontin-
ued imatinib during the study period because of efficacy 
concerns (N = 8) or tolerance problems (N = 5), which 
were already present at inclusion in three and four patients, 
respectively (details: Table 4).
Mean daily imatinib dose at study inclusion was 
404 mg, with 45/56 (80 %) of patients receiving 400 mg, 
and six and five patients receiving lower and higher 
doses, respectively. During the study, dosage increase and 
decrease was proposed to 24 and 4 patients, respectively 
(17 and 2 to “routine,” 7 and 2 to “rescue” TDM patients, 
respectively; mean daily dosage recommended: 485 mg). 
At study end 7/43 (63 %) of patients remained on standard 
dose imatinib, while 3 and 13 patients received lower and 
higher doses, respectively (mean daily dosage: 444 mg).
Measured plasma concentrations and individual pre-
dicted Cmin are illustrated in the Online Resource 2, and 
AEs reported during the study are listed in Table 2.
Primary outcome
Globally, 13/27 of patients receiving “routine TDM” 
remained event-free during the study course (48 %), com-
pared with 16/28 patients receiving only “rescue TDM” 
(57 %; absolute risk difference: +9 %, 95 % confidence inter-
val: [−21 to +39 %], P = 0.69). Out of those, 6/27 patients 
(21 %) in the “routine TDM” and 5/28 (18 %) in the “rescue 
TDM” group are presented already with an event at inclusion. 
In the subgroup analysis of the “routine TDM” group, 10/14 
of patients receiving the recommended dosage after one 
cycle of TDM remained event-free (71 %), compared with 
3/13 patients who did not or only partially receive the recom-
mended dosage (23 %; absolute risk reduction: −48 % [−8 to 
−89 %], P = 0.033). A longitudinal presentation is shown in 
Fig. 3.
Secondary outcomes
The decline of median BCR-ABL/ABL transcript lev-
els was rather small in both groups (0.48 log10 reduc-
tion in the control, 0.32 log10 reduction in the inter-
vention group, P = 0.32). There were no differences 
Fig. 1  Schematic representation of dosage recommendation proce-
dure. 1Fractioning the total daily dose into two intakes allows achiev-
ing higher Cmin and lower Cmax than under a single intake per day. 2A 
compliance check was especially proposed if the concentration was 
unexpectedly low considering age, body weight and gender [18, 34]
Cmin below target 
(≤ 750 ng/mL)
Cmin 650-750 ng/mL
Cmin <  550 ng/mL
Dose increase by x 2 and/or 
dose fraconing1
(e.g. increase from 400 mg/24h to 
800 mg/24h or to 300-400 mg/12h) 
Or possibly: check compliance2
Dose increase by x 1.5 
(e.g. increase from 400 to 600 mg)
Dose increase by x 1.25 
(e.g. increase from 400 to 500 mg)
Cmin within target interval 
(750 – 1500 ng/mL)
Significant AEs: 
≥grade 2 clinical or 
≥grade 3 laboratory
Connue current dose
Dose decrease by x 0.5-0.75 
and possibly dose fraconing?
(eg. decrease from 400 mg to 300 
mg/24h or 100mg/8h-12h)
no significant 
adverse event (AE)
Cmin above target 
(>1500 ng/mL) 
Control plasma 
concentraon aer ? 1 week regular 
drug intake
Control plasma 
concentraon in case 
of problems or at 
study end the latest
Cmin 550-650 ng/mL
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between groups with respect to other secondary clinical 
outcomes or in Cmin at study end (Table 3). In the “rou-
tine TDM” group, 9/13 (69 %) of patients who received 
recommended dosage had Cmin in the target range at 
study end versus 4/10 (40 %) of those who did not or 
only partially receive the recommended dosage (Fig. 4). 
Cumulative efficacy and toxicity events did not differ 
statistically between patients with average high or low 
(≥/<median) total or unbound imatinib Cmin. However, 
there was a trend toward a higher proportion of treatment 
failures in patients with lower unbound Cmin. Conversely, 
AEs tended to be more frequent in patients with higher 
unbound Cmin (Online Resource 2). Secondary outcomes 
and dosage modifications during the study are illustrated 
in Online Resource 2.
Discussion
I-COME is the first randomized controlled trial having pro-
spectively investigated the clinical benefit of one cycle of 
“routine TDM” for dosage individualization of imatinib 
targeting a Cmin of 1,000 ng/ml [19, 20] (tolerance interval: 
750–1,500 ng/ml). Such a trial has been repeatedly called 
for in CML patients receiving imatinib and for other targeted 
anticancer agents [21–24, 30]. The trial was not able to dem-
onstrate a significant benefit of “routine TDM” in compari-
son with usual treatment management (“rescue TDM” only 
in case of clinical problems), in terms of event-free survival 
(combined efficacy, safety and persistence outcome) after 
1-year follow-up. The main study limitations are the low 
number of patients enrolled and the limited prescriber’s 
Fig. 2  Trial diagram. TDM, therapeutic drug monitoring. Solid black 
boxes intervention group (“routine TDM” at inclusion). Gray boxes 
control group (“rescue TDM” only). Dashed black box routine TDM 
patients having not or only partially received the recommended dos-
age during the study. 1No absolute numbers can be given due to the 
multicenter study design having proposed the study to both clinic- 
and practice-based hematologists throughout Switzerland. 2Patients 
having only partially received recommended dosage (n = 8) include 
patients that either received a dosage change following our recom-
mendation, but not the exact recommended dosage, or received the 
recommended dosage with a sizeable delay. Patients not having 
received recommended dosage did never receive any dosage accord-
ing to our recommendations
Assessed for eligibility1
esmated from annual incidence of CML:
400-600 cases CML with diagnose 
< 5 years in Switzerland
Randomized (n=56)
+ inclusion plasma sample of every paent
Excluded1
Possible reasons for not parcipang:
• Paent not meeng inclusion criteria: 
oCML paent not on imanib < 5 years
oage < 18 years
opregnancy, breaseeding 
opaent not willing to parcipate
• Physician in charge not willing to 
parcipate
• Physician did not receive informaon
28 allocated to intervenon « roune TDM »: transmission of 
Cmin result & dosage recommendaon, target Cmin: 1000 ng/ml 
(tolerance interval: 750-1500 ng/ml)
28 allocated to control « rescue TDM »: no transmission of Cmin
result or dosage recommendaon, unless specifically requested 
because of clinical concerns
13 did not or only parally2
receive recommended dosage
3 disconnued imanib
reason: 3 adverse events
15 received recommended 
dosage
2 disconnued imanib
reason: 1  failure, 1 warnings
27 paents included in analysis (intenon-to-treat) 28 paents included in analysis (intenon-to-treat)
1 excluded from 
primary outcome 
(response not 
available)
8 requested TDM at 
inclusion
reason: 2 adverse 
events, 3 subopmal 
response, 3 warnings
5 disconnued 
imanib 
reason: 2 adverse 
events, 2 subopmal 
response, 1 warnings
4 requested TDM 
during study
reason: 1 subopmal 
response, 3 warnings
2 disconnued 
imanib 
reason: 1 subopmal 
response, 1 warnings
16 did not 
request TDM
1 disconnued 
imanib
reason: failure
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adherence to dosage recommendations in the “routine TDM” 
group. Only 50 % of patients allocated to routine TDM inter-
vention actually received the recommended imatinib dosage, 
which was nevertheless associated with better achievement 
of target concentrations and reduced risk (−48 %) of unfa-
vorable events (treatment failure, moderate clinical or severe 
laboratory AEs or imatinib discontinuation).
Limited feasibility of adequate patient recruitment in 
such trials has been previously reported [31]. This may 
be mainly attributable to the outpatient setting and the 
response and tolerability being considered satisfying in 
most patients. Additionally, the emergence of second gen-
eration TKIs may have reduced the interest for imatinib 
dosage optimization interventions. Such interventions 
remain rather complex and time-consuming—according 
to either pharmacodynamic or pharmacokinetic response 
markers. In our study, the relatively longtime elapsing 
between routine medical visits (usually 3 months) might 
have complicated dosage adjustments, despite oral and 
written communication of recommendations. Moreover, 
TDM hardly belongs at present to the culture of oncologi-
cal patient management.
Table 1  Patient and sample 
characteristics
Continuous variables are 
summarized as median (inter-
quartile range)
Cmin, imatinib trough 
concentration; n, number of 
patients
a
 Not significantly different 
(22.9 vs. 23.1 months, 
P = 0.96, Welch t test)
b
 The number of samples 
corresponds to the number 
of TDM occasions in the 
respective group, which is 
higher in the intervention group 
through the study design (in the 
intervention group TDM could 
be performed at any time and 
results were always transmitted; 
in the control group samples 
were requested at inclusion and 
study end only; TDM results 
during the study were only 
transmitted on specific request 
in case of clinical concerns)
c
 Predicted using a validated 
Bayesian TDM method, tak-
ing into account gender, body 
weight and age for prior predic-
tions Gotta et al. [26]
d
 Predicted using a population 
PK model taking into account 
α1-acid glycoprotein concentra-
tions (Haouala et al. 2012)
Control group (N = 28) Intervention group (N = 28)
Patient characteristics
Male:female (N) 15:13 13:15
Age (years) 53 (44–64) 59 (49–73)
Body weight (kg) 72 (64–87) 77 (63–84)
Duration of imatinib treatment at inclusion (months)
 0–18 months (N) 11 12
 >18–36 months (N) 10 10
 >36–60 months (N) 7 6
Months since initial CML diagnosis at inclusion 19.5 (7.8–35.5)a 24.5 (6.8–34)a
Sokal score (N)
 High (>1.2) 1 7
 Medium (0.8–1.2) 14 10
 Low (<0.8) 7 7
 Not available 6 4
Initial treatment other than standard dose imatinib (N)
 Imatinib >400 mg 1 1
 Hydroxyurea pretreatment 7 9
 Interferon 1 2
Imatinib daily dose at inclusion
 <400 mg 0 6
 400 mg 24 20
 >400 mg 4 2
Sample (imatinib concentration) characteristics
Total numbers of samplesb (N) 60 81
 Patients with at least 1 sample (inclusion sample) 28 28
 Patients with at least 2 samples 25 25
 Patients with 3 samples or more 5 17
Imatinib daily dose
 <400 mg 0 17
 400 mg 45 46
 >400 mg 15 18
Measured total imatinib concentration (ng/ml) 1,612 (1,118–2,139) 1,093 (747–1,555)
Measured unbound imatinib concentration (ng/ml) 46 (32–67) 30 (21–47)
Time after last dose intake (h) 7.8 (4.5–16.1) 13 (6.5–22.2)
Predicted imatinib total Cmin (ng/ml]c 801 (610–1,107) 758 (578–1,013)
Predicted unbound imatinib Cmin (ng/ml)d 22 (13–31) 23 (18–30)
α1-acid glycoprotein concentration (g/l) 0.89 (0.75–1.04) 0.84 (0.76–1.00)
1313Cancer Chemother Pharmacol (2014) 74:1307–1319 
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The event rate according to the primary outcome 
was higher than expected in this treatment experienced 
patient population receiving imatinib since a median of 
1.5–2 years. Importantly, about half of the events repre-
sented imatinib discontinuation, with 23 % of patients in 
total having stopped the drug during the 1-year follow-up 
(compared with 28 % during 5 years reported [32]), prob-
ably encouraged by the availability of second generation 
TKIs [33]. We acknowledge that this could additionally be 
attributed to one of the following reasons: First, the trial 
Table 2  Adverse events reported during the study in the 56 patients included
N total number of patients
a
 The maximum grade for each patient is reported. n: number of patients with adverse event
Total (N = 56) TDM group (N = 28) Control group (N = 28) P value
Any grade n (%) Grade 2 (grade 3) Any grade (n) Grade 2[3] (n) Any grade (n) Grade 2[3] (n) Fisher’s exact test
Hematologic/laboratory adverse eventsa
Anemia 24 (43 %) 1 (2 %) 14 – 10 1 0.60
Neutropenia 7 (13 %) 1 (2 %) [1 (2 %)] 4 −[1] 3 1 1
Thrombocytopenia 7 (13 %) 1 (2 %) 5 1 2 – 0.43
Increased liver  
enzymes
7 (13 %) 1 (2 %) 5 – 2 1 0.43
Clinical adverse eventsa
Fluid retention/periph-
eral edema
28 (50 %) 5 (9 %) 14 4 14 1 1
Muscle cramps/ 
arthralgia
24 (43 %) 6 (11 %) 16 3 8 3 0.30
Fatigue/weakness/
insomnia
19 (34 %) 6 (11 %) 10 2 9 3 1
Diarrhea/abdominal 
cramps
13 (23 %) 2 (4 %) 8 2 5 – 0.54
Skin rash/pruritus 10 (18 %) 3 (5 %) 8 2 2 1 0.097
Nausea/vomiting/ 
dyspepsia
8 (14 %) 2 (4 %) 5 2 3 – 0.71
Headache/dizziness 3 (5·4 %) 0 1 – 2 – 1
Fig. 3  Longitudinal presentation of the primary outcome (Kaplan–
Meier plots): patients remaining event-free, i.e., without failure, 
occurrence of moderate (grade 2) clinical or severe (grade 3) labora-
tory adverse events, or discontinuation of treatment. a Intention-to-
treat analysis: number of events in the control group 12/28 (gray line) 
versus 14/27 in the intervention group (black line). b Subgroup analy-
sis in intervention group: number of events in patients who received 
recommended dosage 4/14 (solid black line = per-protocol) versus 
patients who not or partially received recommended dosage 10/13 
(dashed black line)
1314 Cancer Chemother Pharmacol (2014) 74:1307–1319
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Table 3  Secondary outcomes
n/N number of patients with event (n) out of the total number of patients considered (N)
a
 Measured or expected on the basis of the quantitative molecular response measurement
b
 One patient having stopped imatinib in the intervention group because of tolerance problems, but not having presented with grade 2 AEs at the 
time of the last study visit, was counted as adverse event grade 2, too
c
 Clinical concerns: at inclusion: motivation to participate in study efficacy or toxicity concerns or drug–drug interaction, documented subopti-
mal response or warnings or failure, laboratory grade 3 or clinical grade 2 events; at study end: documented suboptimal response or warnings or 
failure, laboratory grade 3 or clinical grade 2 events during study, treatment discontinuation
Control group (N = 28)  
[% (n/N)]
Intervention group 
(N = 28) [% (n/N)]
P value  
(Fisher’s exact test)
% Achieving major molecular response (MMR)
With MMR at inclusion 63 % (17/27) 62 % (16/26)
Achieving MMR out of those without MMR at inclusion 40 % (4/10) 20 % (2/10) 0.63
% Achieving complete cytogenetic response (CCR)a
With CCR at inclusion 78 % (21/27) 69 % (18/26)
Achieving CCR out of those without CCR at inclusion 60 % (3/5) 75 % (6/8) 1
% Remaining without moderate (≥grade 2) adverse events (AE) of any kind
Without moderate AEs at inclusion 86 % (24/28) 82 % (23/28)
Without moderate AEs during the whole studyb 79 % (19/24) 74 % (17/23) 1
% With clinical concernsc at inclusion and % presenting an improvement
With clinical concerns at inclusion 39 % (11/28) 39 % (11/28)
Presenting an improvement during study 36 % (8/11) 18 % (2/11) 0.64
% With imatinib Cmin in the target range
Within 750–1,500 ng/ml at inclusion 39 % (11/28) 46 % (13/28)
Within 750–1,500 ng/ml at study end 55 % (11/20) 52 % (12/23) 1
Achieving 750–1,500 ng/ml out of those not in interval at inclusion 27 % (3/11) 42 % (5/12)
>1,000 ng/ml at inclusion 32 % (9/28) 21 % (6/28)
>1,000 ng/ml at study end 35 % (7/20) 22 % (6/28) 0.50
Fig. 4  a Predicted imatinib Cmin at inclusion and at study end in 
the intervention group (black boxes “routine TDM”) and the con-
trol group (gray boxes “rescue TDM”); dots represent patients hav-
ing stopped imatinib treatment. Whiskers extend up to 1.5 times the 
inter-quartile range. n number of patients represented. Median Cmin 
(CV %) Intervention group inclusion: 802 ng/ml (CV = 44 %), study 
end: 766 ng/ml (CV = 39 %). Control group inclusion: 719 ng/ml 
(CV = 55 %), study end: 818 ng/ml (CV = 43 %). The eight patients 
who discontinued imatinib for efficacy concerns had a median Cmin of 
711 ng/ml (CV = 51 %) and the five patients having stopped imatinib 
for tolerance concerns had a median Cmin of 384 ng/ml (CV = 84 %); 
overall median Cmin 633 ng/ml (41 %). b Subgroup analysis in inter-
vention group: patients who received recommended dosage (dark 
gray), median Cmin (CV %): 895 ng/ml (33 %), versus patients who 
not or partially received the recommended dosage (gray), median 
Cmin (CV %): 648 ng/ml (38 %)
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was possibly attractive for patients with clinical concerns 
since it offered TDM free of charge. Second, performing 
several TDM cycles in “routine TDM” patients may have 
falsely increased the adverse event rate, since AEs were 
essentially reported with TDM requests entailing a fluctua-
tion of their grading between mild and moderate in some 
patients. Notably, more patients in the intervention group 
were treated with a low imatinib dose at inclusion, suggest-
ing previous tolerance problems.
Consistently, imatinib was mainly discontinued because 
of AEs in the intervention group (3 out of five patients). 
Conversely, in the control group, imatinib was mainly 
discontinued because of efficacy problems (six out of 
eight patients), whereas MMR, CCR rates and treatment 
durations were similar at inclusion in both groups. This 
could indicate that routine TDM mainly prevents treat-
ment failure, while its usefulness for reducing AEs could 
be limited when targeting Cmin of 750–1,500 ng/ml in all 
patients. Among patients not receiving the recommended 
dosage, 60 % had concentrations below this interval and 
were partly characterized by a complex condition, result-
ing in difficulties to apply strict TDM rules. For example, 
two patients having stopped imatinib for tolerance prob-
lems (patient 4–5, Table 4) were not eligible for dosage 
increase despite low concentrations. In contrast, early TDM 
may have prevented insufficient efficacy in two young 
male patients with important body weight, since Cmin was 
particularly low under standard doses of imatinib (patient 
8 and 12, Table 4). Very low concentrations (≤520 ng/ml) 
are actually expected in about 25 % of patients on imatinib 
standard dose and are more likely in corpulent young male 
patients [18, 34]. In the IRIS study, 25 % of patients with 
low Cmin 1 month after treatment start (<650 ng/ml) had 
lower optimal response rates at 12 and 18 months [19] and 
a higher discontinuation rate due to unsatisfactory effect.
A systematic review found evidence from observational 
studies that individual Cmin correlates with treatment outcome 
in CML patients, especially when considering early thera-
peutic response [18]. No prospective evaluation of dosage 
modifications according to individual Cmin as pharmacoki-
netic marker is, however, available to compare our results. 
We are only aware of one study being still ongoing (OPTIM, 
EudraCT: 2010-019568-35). Dosage escalation according 
to pharmacodynamic markers (hematologic and cytogenetic 
responses) has been reported to induce a response in 40 % of 
patients and an 89 % progression-free survival at 3 years [35, 
36]. In selected imatinib-resistant patients receiving imatinib 
up to >3 years, the clinical benefit of dosage escalation may 
be lower [37], suggesting an interest for early escalation. In 
our study, only 2/11 (18 %) of patients in the routine TDM 
group reported an improvement of safety or efficacy issues 
over 1 year (Table 3), with the possible bias of non-adjusted 
dosage and fluctuating AEs reporting.
Secondary outcomes indicated high response levels 
in the majority of patients already at inclusion and thus a 
limited room for improvement: 80 % of patients were in 
CCR and almost two thirds in MMR, i.e., close to maxi-
mal cumulative response rates described [19]. Additionally, 
patients markedly intolerant to imatinib, in whom rapid 
treatment discontinuation was preferred to slow dosage 
readjustment, may have escaped our study. As TDM inter-
vention decreases pharmacokinetic variability, exposure–
response associations in this prospective study are expected 
to be weakened. Still, though not statistically significant, 
relationships of unbound Cmin with clinical outcomes were 
stronger than with total Cmin. The monitoring of unbound 
Cmin could thus receive further consideration in the future, 
and its usefulness deserves formal evaluation [38]. Phar-
macogenetic markers affecting drug transport across cell 
membranes might additionally be taken into account 
[39–41].
Based on the individual experience accumulated 
throughout our study, and despite its limitations men-
tioned above, we think that TDM can valuably contribute 
to patient management during imatinib treatment. Measur-
ing imatinib Cmin 1–3 months after treatment initiation (at 
best after blood count normalization to decrease pharma-
cokinetic variability) can provide an individual baseline 
level of drug exposure and correct gross under- or overex-
posure. A similar proposal for patients with gastrointesti-
nal stromal tumor treated with imatinib has recently been 
made [42]. This can later help to evaluate adherence and 
drug interaction problems and to optimize systemic drug 
exposure in patients not responding as expected or devel-
oping toxic symptoms. It is noteworthy in this respect that 
the latest treatment recommendations [33] emphasize the 
importance of managing also low-grade adverse events 
with attention, to improve quality of life and compliance. 
This trial was not designed specifically to investigate the 
benefits of TDM on compliance or drug–drug interaction 
management—two factors that have been found important 
for clinical outcomes in CML patients [34, 43]. Further tri-
als are still needed to confirm the possible benefits of TDM 
in this regard.
Our study highlights both the feasibility and the chal-
lenges to prospectively evaluate the benefit of a routine 
monitoring program for a commercialized drug. The inno-
vative and ethical design of the study, not totally depriv-
ing patients from already available TDM in case of con-
cerns, has allowed recruiting a fair number of patients 
despite the rare indication and the outpatient setting. We 
suggest to treat the outcome “imatinib discontinuation” 
separately in future trials, as TDM may actually encour-
age drug discontinuation in patients intolerant despite 
acceptable plasma levels. Furthermore, differentiating 
between efficacy and safety outcomes (possibly also for 
1316 Cancer Chemother Pharmacol (2014) 74:1307–1319
1 3
Ta
bl
e 
4 
 
Ch
ar
ac
te
ris
tic
s o
f p
at
ie
nt
s h
av
in
g 
di
sc
on
tin
ue
d 
im
at
in
ib
 tr
ea
tm
en
t
R
ef
G
Ch
ar
ac
te
ris
tic
s
Tr
ea
tm
en
t 
du
ra
tio
n 
(m
on
ths
)
M
ai
n 
pr
ob
le
m
(s)
 (i
ma
tin
ib 
 
do
sa
ge
 d
ur
in
g 
tre
at
m
en
t)
C m
in
 
 
(ng
/m
l)
D
os
e 
 
(m
g/d
ay
)
TD
M
c
To
le
ra
nc
e
Ef
fic
ac
y
Co
m
m
en
ts
D
is
co
nt
in
ua
tio
n 
for
 in
tol
era
n
ce
 m
a
in
ly
1
C r
M
, 7
9 
ye
ar
s, 
70
 
kg
4a
In
to
le
ra
nc
e 
(40
0 m
g)
15
9
40
0
A
dh
er
en
ce
D
ys
gu
es
ia
 G
2
CH
R
CC
R
Se
v
er
al
 c
om
or
bi
di
tie
s 
an
d 
co
m
ed
ic
at
io
n
2
C r
F,
 
48
 
ye
ar
s, 
50
 
kg
20
a
In
to
le
ra
nc
e 
(40
0–
60
0 m
g)
Su
bo
pt
im
al
 re
sp
on
se
1,
60
0
60
0
50
0
M
ai
n 
is
su
e:
 P
le
ur
al
 e
ffu
sio
n 
G
2/
3 
(no
 ho
sp
ita
liz
ati
on
);
Se
v
er
al
 o
th
er
 A
Es
 G
1–
2 
(ra
sh
, 
th
ro
m
bo
p.
, a
no
re
x
ie
, e
de
m
a,
 
an
em
ia
, n
eu
tro
p.
)
CC
R
n
o
 M
M
R
Pa
tie
nt
 in
to
le
ra
nt
 to
 
o
th
er
 T
K
Is
 a
s w
el
l
3
I
M
, 4
6 
ye
ar
s, 
77
 
kg
8a
In
to
le
ra
nc
e 
(20
0–
80
0 m
g)
38
0
20
0
40
0
se
v
er
al
 A
Es
 G
1–
2 
(an
em
ia,
 
ra
sh
, m
ya
lg
ia
, h
ea
da
ch
e,
 
n
au
se
a,
 fa
tig
ue
)
CC
R
n
o
 M
M
R
4
I
F,
 
64
 
ye
ar
s, 
84
 
kg
24
In
to
le
ra
nc
e 
(30
0–
40
0 m
g)
(su
bo
pti
ma
l r
esp
on
se)
54
5
56
0
59
0
40
0
40
0
30
0
A
dh
er
en
ce
?
60
0
M
ai
n 
is
su
e:
 G
2 
ra
sh
/p
ru
rit
us
se
v
er
al
 o
th
er
 A
Es
 G
1–
2 
 
(m
ya
lgi
a, 
ex
tr
as
ys
to
lie
s)
CC
R 
(no
 M
M
R 
 
%
 
 
Ib )
5
I
M
, 6
8 
ye
ar
s, 
84
 
kg
7a
In
to
le
ra
nc
e 
(20
0–
40
0 m
g)
37
0
20
0
50
0
G
3 
cy
to
to
xi
ci
ty
M
M
R
In
se
rti
on
 p
b1
78
7
D
is
co
nt
in
ua
tio
n 
for
 ef
fic
ac
y c
on
ce
rn
s m
ain
ly
6
I
M
, 7
7 
ye
ar
s, 
77
 
kg
46
W
ar
n
in
g 
(40
0 m
g)
(su
bo
pti
ma
l r
esp
on
se)
86
0
84
0
40
0
40
0
40
0
50
0
G
1–
2 
Si
cc
a 
sy
nd
ro
m
e 
of
 th
e 
ey
es
↑B
CR
-A
BL
(no
 M
M
R 
 
%
 IS
b )
M
ut
at
io
n 
sc
re
en
in
g 
n
eg
at
iv
e
7
C r
F,
 
41
 
ye
ar
s, 
67
 
kg
50
a
W
ar
n
in
g 
(20
0–
50
0 m
g)
(su
bo
pti
ma
l r
esp
on
se)
67
0
83
0
93
0
40
0
40
0
50
0
50
0
50
0
50
0
–
↑B
CR
-A
BL
 (n
o 
M
M
R
  %
 IS
b )
8
C
M
, 4
4 
ye
ar
s, 
11
2 
kg
50
Pr
og
re
ss
io
n 
(40
0 m
g)
22
0
40
0
80
0 
(2 
× 
40
0)
–
N
o 
M
M
R,
 ↑B
CR
-
A
BL
, P
Cy
R
Tr
iso
m
ie
 8
, p
lu
s a
dd
i-
tio
na
l a
bn
or
m
al
iti
es
9
C r
M
, 7
8 
ye
ar
s, 
64
 
kg
20
Su
bo
pt
im
al
 re
sp
on
se
  
(40
0–
60
0 m
g)
75
0
1,
20
0
1,
19
0d
40
0
60
0
50
0
50
0
50
0–
60
0
G
1 
ra
sh
, t
hr
om
bo
p.
, n
eu
tro
p.
, 
an
em
ia
N
o 
M
M
R 
(C
CR
 
ex
pe
ct
ed
)
M
ut
at
io
n 
sc
re
en
in
g 
n
eg
at
iv
e,
 c
el
ia
c 
di
se
as
e
10
I
F,
 
80
 
ye
ar
s, 
69
 
kg
14
Fa
ilu
re
 (4
00
 
m
g)
1,
32
0
40
0
40
0
G
1 
ed
em
a,
 li
v
er
 e
n
zy
m
es
, 
an
em
ia
Lo
ss
 o
f C
CR
n
o
 M
M
R
R
es
ist
an
t A
BL
 
m
u
ta
-
tio
n 
de
te
ct
ed
se
v
er
al
 c
om
or
bi
di
tie
s
11
C r
F,
 
51
 
ye
ar
s, 
92
 
kg
23
Su
bo
pt
im
al
 re
sp
on
se
  
(40
0–
60
0 m
g)
To
le
ra
nc
e 
pr
ob
le
m
s (
60
0 m
g)
63
0+
1,
41
0
40
0
60
0
(50
0–
60
0)
G
1–
2 
ed
em
a,
 fa
tig
ue
, m
ya
lg
ia
, 
di
ar
rh
ea
N
o 
M
M
R 
(C
CR
 
ex
pe
ct
ed
)
M
ut
at
io
n 
sc
re
en
in
g 
n
eg
at
iv
e
12
C r
M
, 3
6 
ye
ar
s, 
92
 
kg
19
Su
bo
pt
im
al
 e
es
po
ns
e
51
0
40
0
60
0
G
1 
fa
tig
ue
, G
2 
liv
er
 e
n
zy
m
es
N
o 
M
M
R 
(C
CR
 
ex
pe
ct
ed
)
1317Cancer Chemother Pharmacol (2014) 74:1307–1319 
1 3
target plasma levels), restricting the inclusion to a treat-
ment naïve patient population and investigating reasons 
for prescribers’ non-adherence to dosage recommenda-
tions would probably improve the design and power to 
evaluate the impact of TDM on patient’s outcomes. Such 
trial design could thus represent an interesting framework 
to develop similar, larger studies for many newer antican-
cer agents [15, 23, 24, 44]. International multicenter col-
laborations will probably be needed to recruit appropriate 
numbers of patients.
In conclusion, while this first prospective target con-
centration intervention trial could not formally demon-
strate a benefit of “routine TDM” of imatinib, especially 
due to a small patient number and limited prescriber’s 
adherence to dosage recommendations, we observed that 
the patients actually applied the advised dosages more 
often met the target concentrations and the combined out-
come (efficacy, tolerance and persistence). A cycle of rou-
tine TDM could thus be favorable in patients eligible to 
dosage adjustment.
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